May 31, 2022
Article
Four lessons learned from the AIDS crisis that can be applied to the fight against our current pandemic.
May 26, 2022
The specialty of the prescribing clinician played a role in the appropriateness of the prescribing for managing ARI in patients with and without HIV.
May 21, 2022
Video
In a poster presented at MAD-ID 2022, Margaret Pertzborn, PharmD, evaluated the efficacy of a PrEP Provider Toolkit on non-infectious disease provider comfort prescribing PrEP with their patients.
May 18, 2022
The FDA lifted a clinical hold on investigational lenacapavir for HIV treatment and pre-exposure prophylaxis. All clinical studies evaluating injectable lenacapavir can now resume.
Today, the International AIDS Vaccine Initiative (IAVI) and Moderna announced they will soon launch a phase 1 clinical trial for their HIV vaccine candidate, administered with mRNA technology to develop broadly neutralizing antibodies.
May 12, 2022
In Part 2 of a video interview, Sornana Segal-Maurer, MD, discusses the newly published research findings that detail the potential of lenacapavir.
Risk-informed PrEP would reduce HIV incidence by 49 percent over the next 50 years, the study authors found.
May 11, 2022
Could lenacapavir be the answer for people with multidrug-resistant HIV infection? Principal investigator Sorana Segal-Maurer discusses the promising trial results in this challenging cohort (Interview part 1).
May 10, 2022
In a study of 32 patients with fourth-line metastatic colorectal cancer, the HIV drug lamivudine slowed disease progression in a quarter of participants.
May 09, 2022
Children living with HIV had a similar immune response to mRNA COVID-19 vaccination as children without HIV.
Monkeypox Symptoms in London Patients Differ from Prior Outbreaks
How COVID-19 Infiltrates and Inflames the Heart
Top 5 Infectious Disease Stories of the Week: July 1, 2022
Communities With More Racial Prejudice Have Worse Health Outcomes
